Cargando…

Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects

A cell-based process may be better suited for vaccine production during a highly pathogenic avian influenza (HPAI) pandemic. This was a phase 3, randomized, controlled, observer-blind, multicenter study evaluated safety, immunogenicity, and lot-to-lot consistency of two doses of a MF59-adjuvanted, H...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterson, James, Van Twuijver, Esther, Versage, Eve, Hohenboken, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027673/
https://www.ncbi.nlm.nih.gov/pubmed/35455245
http://dx.doi.org/10.3390/vaccines10040497
_version_ 1784691425057701888
author Peterson, James
Van Twuijver, Esther
Versage, Eve
Hohenboken, Matthew
author_facet Peterson, James
Van Twuijver, Esther
Versage, Eve
Hohenboken, Matthew
author_sort Peterson, James
collection PubMed
description A cell-based process may be better suited for vaccine production during a highly pathogenic avian influenza (HPAI) pandemic. This was a phase 3, randomized, controlled, observer-blind, multicenter study evaluated safety, immunogenicity, and lot-to-lot consistency of two doses of a MF59-adjuvanted, H5N1 influenza pandemic vaccine manufactured on a cell culture platform (aH5N1c) in 3196 healthy adult subjects, stratified into two age groups: 18 to <65 and ≥65 years. Immunogenicity was measured using hemagglutination inhibition (HI) titers. HI antibody responses increased after the first aH5N1c vaccine dose, and 3 weeks after the second vaccination (Day 43), age-appropriate US Center for Biologics Evaluation and Research (CBER) and former European Medicines Authority Committee for Medicinal Products for Human Use (EMA CHMP) immunogenicity criteria were met. Six months after the first vaccination, HI titers were above baseline but no longer met CBER and CHMP criteria. No relevant changes over time were seen in placebo subjects. Solicited AEs were more frequent in the active treatment than the placebo group, primarily due to injection site pain. No serious adverse events (SAEs) related to aH5N1c- were reported. aH5N1c influenza vaccine elicited high levels of antibodies following two vaccinations administered 21 days apart and met both CBER and former CHMP immunogenicity criteria at Day 43 among both younger and older adults with a clinically acceptable safety profile. Consistency of the three consecutive aH5N1c vaccine lots was demonstrated (NCT02839330).
format Online
Article
Text
id pubmed-9027673
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90276732022-04-23 Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects Peterson, James Van Twuijver, Esther Versage, Eve Hohenboken, Matthew Vaccines (Basel) Article A cell-based process may be better suited for vaccine production during a highly pathogenic avian influenza (HPAI) pandemic. This was a phase 3, randomized, controlled, observer-blind, multicenter study evaluated safety, immunogenicity, and lot-to-lot consistency of two doses of a MF59-adjuvanted, H5N1 influenza pandemic vaccine manufactured on a cell culture platform (aH5N1c) in 3196 healthy adult subjects, stratified into two age groups: 18 to <65 and ≥65 years. Immunogenicity was measured using hemagglutination inhibition (HI) titers. HI antibody responses increased after the first aH5N1c vaccine dose, and 3 weeks after the second vaccination (Day 43), age-appropriate US Center for Biologics Evaluation and Research (CBER) and former European Medicines Authority Committee for Medicinal Products for Human Use (EMA CHMP) immunogenicity criteria were met. Six months after the first vaccination, HI titers were above baseline but no longer met CBER and CHMP criteria. No relevant changes over time were seen in placebo subjects. Solicited AEs were more frequent in the active treatment than the placebo group, primarily due to injection site pain. No serious adverse events (SAEs) related to aH5N1c- were reported. aH5N1c influenza vaccine elicited high levels of antibodies following two vaccinations administered 21 days apart and met both CBER and former CHMP immunogenicity criteria at Day 43 among both younger and older adults with a clinically acceptable safety profile. Consistency of the three consecutive aH5N1c vaccine lots was demonstrated (NCT02839330). MDPI 2022-03-23 /pmc/articles/PMC9027673/ /pubmed/35455245 http://dx.doi.org/10.3390/vaccines10040497 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Peterson, James
Van Twuijver, Esther
Versage, Eve
Hohenboken, Matthew
Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects
title Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects
title_full Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects
title_fullStr Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects
title_full_unstemmed Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects
title_short Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects
title_sort phase 3 randomized, multicenter, placebo-controlled study to evaluate safety, immunogenicity, and lot-to-lot consistency of an adjuvanted cell culture-derived, h5n1 subunit influenza virus vaccine in healthy adult subjects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027673/
https://www.ncbi.nlm.nih.gov/pubmed/35455245
http://dx.doi.org/10.3390/vaccines10040497
work_keys_str_mv AT petersonjames phase3randomizedmulticenterplacebocontrolledstudytoevaluatesafetyimmunogenicityandlottolotconsistencyofanadjuvantedcellculturederivedh5n1subunitinfluenzavirusvaccineinhealthyadultsubjects
AT vantwuijveresther phase3randomizedmulticenterplacebocontrolledstudytoevaluatesafetyimmunogenicityandlottolotconsistencyofanadjuvantedcellculturederivedh5n1subunitinfluenzavirusvaccineinhealthyadultsubjects
AT versageeve phase3randomizedmulticenterplacebocontrolledstudytoevaluatesafetyimmunogenicityandlottolotconsistencyofanadjuvantedcellculturederivedh5n1subunitinfluenzavirusvaccineinhealthyadultsubjects
AT hohenbokenmatthew phase3randomizedmulticenterplacebocontrolledstudytoevaluatesafetyimmunogenicityandlottolotconsistencyofanadjuvantedcellculturederivedh5n1subunitinfluenzavirusvaccineinhealthyadultsubjects